ICU MEDICAL INC/DE (ICUI) stock intrinsic value fair value estimate & owner earnings analysis

ICU Medical makes the equipment and disposables used to deliver drugs and fluids into a patient's veins: infusion pumps (Plum, MedFusion syringe pumps, CADD ambulatory pumps), the IV sets and needle-free connectors that go with them, and a range of critical-care products such as tracheostomy tubes, vascular access devices and oncology closed-transfer systems. It was built through two large purchases: Hospira's infusion business from Pfizer in 2017 and Smiths Medical for about $2.55 billion in January 2022. In 2025 revenue was $2.23 billion, half of it consumables ($1.11 billion), 31% infusion systems ($684 million) and the rest vital care. In May 2025 the company sold 60% of its IV Solutions business to Otsuka for $211 million and kept a 40% stake, used the cash to repay debt, and refinanced its bank loans in October 2025. How we measure earnings. We start from cash generated by operations, strip out working-capital timing swings, charge stock compensation as a real cost, and deduct the capital spending needed to keep the plants and pump fleet running. On that basis owner earnings were $3.43 a share in 2023, $2.85 in 2024 and $4.23 in 2025. Because the company carries heavy debt, we value the business before its lenders and subtract the debt once at the end; adding back cash interest gives about $7.41, $6.94 and $7.59 a share, roughly $170 to $190 million a year. We anchor on the three years since the Smiths Medical deal was absorbed (2023 to 2025), median about $185 million. Earlier years describe a much smaller company and 2022 was distorted by a $201 million inventory build during integration. Amortization of acquired intangibles (about $131 million a year) is added back as a sunk acquisition cost, not an operating cost; however, integration and restructuring cash costs have recurred every year since 2017 and we leave them in as a normal cost of doing business rather than treating them as one-offs. Stock compensation has risen every year, from $15 million in 2016 to $56 million in 2025, and is fully charged. Growth. Owner earnings rose 48% in 2025, but much of that came from working-capital and tax timing, and revenue actually fell 6% because IV Solutions left the consolidated results. The first half of 2026 was stronger (operating cash flow $119 million against $63 million a year earlier) but we do not lift the level on two quarters. We credit no growth in the base case: consumables gains came from new customer installations, which is share gain rather than something already secured, and infusion systems is a replacement-cycle business with strong competitors. Debt. At mid-2026 the company owed about $1.23 billion in term loans (Term Loan A due October 2030, Term Loan B due January 2029, rated B1 by Moody's); cash and short-term investments were $308 million at the end of 2025; with finance leases, a $50 million operating cushion of cash and other obligations we use $1.05 billion. The 40% stake in the Otsuka IV Solutions joint venture is carried at about $129 million and we add $130 million; Otsuka holds a call option on it starting in 2030, so it is likely to be turned into cash at some point. Base case: business cash flow before interest holds near $180 million a year with no growth, as the post-integration record supports, continuing indefinitely because infusion consumables are sold into an installed base of pumps and hospital protocols that rarely switch. The business is worth about $3.0 billion; less $1.05 billion of net debt plus the joint venture stake leaves about $2.08 billion, or roughly $83 a share. Bear case: the April 2025 FDA warning letter over unapproved modifications to the MedFusion 4000 and CADD pumps escalates into shipment holds or recalls, much as the 2021 Smiths Medical warning letter consumed several years of field-action spending, and tariffs on imported medical consumables (the 2025 Section 232 investigation) squeeze margins. Business cash flow falls to $100 million for three years, recovers only to $140 million, and fades to nothing over the following fifteen years as competing pump platforms take share. The business is worth about $1.33 billion against $1.09 billion of debt (including a higher-cost refinancing of the 2029 Term Loan B) plus the joint venture stake, leaving about $15 a share. In this case cash flow still covers interest of roughly $70 million, so lenders would refinance, but little is left for owners. Bull case: the new MedFusion and refreshed CADD Solis clearances arrive, the warning letter closes, and continued consumables installations lift business cash flow from $200 million to $240 million over five years, then hold. The business is worth about $3.9 billion, leaving roughly $119 a share after debt. Margin of safety price. How sure are we of the earnings level? Moderately: three years of post-integration results sit in a narrow band of $170 to $190 million before interest, but those years include integration and restructuring spending that has recurred every year since 2017, and 2025 benefited from working-capital releases. The worst plausible outcome is a regulatory action against its pump lines combined with the 2029 Term Loan B maturity coming due in a tight credit market; because tangible book value is roughly zero and debt is about 3 to 4 times business cash flow, shareholders would bear that almost entirely, which is what the bear case of about $15 shows. If we are wrong about the level (say it is really $150 million) and wrong about the pumps, the shares are worth perhaps $40 to $50. On the positive side, the business generates roughly $100 million a year after interest, about $4 a share, that can go to debt repayment, so value accrues to owners over the holding period even without growth; there is no dividend. The price assumes a three-to-five-year holding period. On those facts the margin-of-safety price is $40: at that price the shares are covered by the business value even if earnings settle about 15% below the recent level, debt repayment alone adds roughly 10% a year to the owners' stake, and a return toward the base value within four or five years would imply well over 20% a year, while the bear case still implies a loss, the portion that cannot be avoided in a leveraged business. Change since our previous analysis. Our previous figures were prepared on a different basis and are not comparable. The business facts since then are mixed: the FDA closed the older 2021 Smiths Medical warning letter in February 2026, which removes one regulatory overhang, while the 2025 warning letter on MedFusion and CADD pumps remains open; first-half 2026 cash generation improved while revenue was lower because IV Solutions is no longer consolidated.